PROXIDRUGS

The PROXIDRUGS consortium is supported by a professional and tightly engaged innovation and transfer management. PROXIDRUGS also supports spin-off activities and the establishment of sustainable, local partnerships... PROXIDRUGS aims at improving this novel class of drugs in multiple ways: the strategy comprises the identification of suitable functional subunits for molecule engineering; the directed optimization of pharmacological properties; and the transfer to clinical phases. In line with this, the cluster interlinks partners from academia and industry, covering the entire value chain from basic to translational research. Academic participants are based at Goethe University Frankfurt, TU Darmstadt, University of Heidelberg, the MPI of Biophysics, and the Fraunhofer Institute for Translational Medicine and Pharmacology. They are closely working together with major pharma partners, namely AbbVie Deutschland, Merck Healthcare, and GlaxoSmithKline, as well as Revvity as a technology..

Primary location: Frankfurt Germany